Overview
SNOA market data
Price History
SNOA price chart · 3M
- O
- 1.38
- H
- 1.40
- L
- 1.33
- C
- 1.35
- Vol
- 1,063.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $1.38
- Previous Close
- $1.39
- Day High
- $1.40
- Day Low
- $1.33
- 52 Week High
- $1.44
- 52 Week Low
- $1.01
- 7 Day Return
- +0.75%
- 30 Day Return
- +17.39%
- 90 Day Return
- +16.38%
- 1 Year Return
- +25.00%
- Daily Notional Volume
- $1.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.89 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.33 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -16.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.85 – $5.04 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.4M · P/B 1.19 · P/S 0.33.
Company News
Sonoma Pharmaceuticals shares are trading higher after the company reported a year-over-year increase in Q1 financial results.Benzinga · Aug 6, 2026, 1:03 PM
Sonoma Pharmaceuticals Q1 EPS $(0.09) Up From $(0.76) YoY, Sales $6.406M Up From $4.015M YoYBenzinga · Aug 6, 2026, 12:34 PM
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly RevenueBenzinga · Aug 6, 2026, 12:33 PM
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance For Its Microdacyn Wound Irrigation SolutionBenzinga · Jun 30, 2026, 1:05 PM
Sonoma Pharmaceuticals Increases Maximum Aggregate Offering Price Of Common Stock To $3.64MBenzinga · Jun 18, 2026, 8:40 PM
8-K filing — Sonoma Pharmaceuticals, Inc. (SNOA)SEC EDGAR · Jun 18, 2026, 8:33 PM
Sonoma Pharmaceuticals Q4 EPS $(0.33) Misses $(0.24) Estimate, Sales $5.561M Miss $5.565M EstimateBenzinga · Jun 16, 2026, 8:20 PM